MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Intermediaries
Private Equity, Investment Banking, Financial Services, Factoring
Analysts, Investment Banks: Top Performing Recommendations & Analysis
Finance & Acquisitions: BAKER BROTHERS ADVISORS LP
GlycoMimetics, Inc. (NASDAQ: GLYC)*
Organization & Developments: Glycomimetics
Parents
GlycoMimetics, Inc. (NASDAQ: GLYC)*
Children
*Capitalizes and builds on advances in the field of glycobiology
*Developed through collaboration between GlyoTech and Ciba-Geigy (later Novartis).
*Glycobiology used to develop small molecule drugs that mimic the actions of carbohydrates.
*GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including AML, and for inflammatory diseases.
*GMI owns or has exclusive licenses to fifteen issued U.S. patents
*The company is focusing its initial efforts on therapeutics to treat inflammatory diseases such as cystic fibrosis and cancer.
2014: GlycoMimetics Announces Presentation of Data on Rivipansel (GMI-1070) in Combination with Current FDA-Approved Treatment for Sickle Cell Disease
2014: Maryland Biotech _ MedImmune, GlycoMimetics and MacroGenics announce cancer drug trials
2014: The big pharma gamble: GlycoMimetics' Rachel King on signing with Pfizer
2017: Biotech Forum Daily Digest: Valeant's Continuing Struggles, Spotlight On GlycoMimetics
2017: FDA Breakthrough Therapy Designation for Adult Relapsed/Refractory Acute Myeloid Leukemia_seekingalpha
2017: GlycoMimetics: Another ASH Winner With Continued Upside - GlycoMimetics (NASDAQ:GLYC)
2017: GlycoMimetics: Buy The Dip - GlycoMimetics (NASDAQ:GLYC)
2017: GlycoMimetics's Year-To-Date Runup Is Just The Beginning - GlycoMimetics (NASDAQ:GLYC)
2018: GlycoMimetics: No Longer ROTY, But Still A Buy_seekingalpha.com
2019: GlycoMimetics shares crash after Pfizer team dismisses their lead drug as a PhIII failure – Endpoints News
2019: Glycomimetics_An Option Strategy On An Oversold ‘Busted IPO’ _gallery.mailchimp.com
2019: GlycoMimetics: Forecasting The Clinical Binary For Rivipansel_seekingalpha.com
2019: GlycoMimetics: Grinding Its Way Back - GlycoMimetics, Inc. (NASDAQ:GLYC)
2020: GlycoMimetics' Possible Rivipansel Revival
2020: The Investment Case For GlycoMimetics
2020: Trial flops see Pfizer cut GlycoMimetics pact, Merck ax KalVista research deal
2021: GlycoMimetics A Buy On Potential 2022 AML Data
2022: GlycoMimetics Could Surge If Q1 Data Readout Is Positiv_ seekingalpha.com
2023: GlycoMimetics: An Asymmetric Opportunity That Could Change Hematology_ seekingalpha.com
2023: GlycoMimetics' Uproleselan: Navigating Clinical And Financial Complexities In AML_ seekingalpha.com
2024: GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma
2024: GlycoMimetics: Drug Approval Is Not Coming In 2024, But The Hype Could Be Real_ seekingalpha.com
2024: GlycoMimetics' AML drug flunks Phase 3 trial, quashing filing plans as stock sinks
Jumps
*Key People: Glycomimetics
Finance & Acquisitions: Glycomimetics